Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co Operating Cash Flow

The Operating Cash Flow of Harbin Pharmaceutical Group Co (600664.SS) as of Nov 15, 2026 is 439.66 M CNY. In the previous year, Operating Cash Flow was 792.50 M CNY — a change of -44.52% (lower).

Operating Cash Flow

439.66 MCNY

YoY

-44.52%

Last updated:

Operating Cash Flow of Harbin Pharmaceutical Group Co is 2025 439.66 M CNY. Operating Cash Flow of Harbin Pharmaceutical Group Co was 2024 792.50 M CNY. It decreases by -44.52% lower compared to the previous year.

The Harbin Pharmaceutical Group Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
692.72 M CNY
Jan 1, 2019
-284.94 M CNY
Jan 1, 2020
-728.15 M CNY
Jan 1, 2021
-162.44 M CNY
Jan 1, 2022
622.09 M CNY
Jan 1, 2023
949.67 M CNY
Jan 1, 2024
792.50 M CNY
Jan 1, 2025
439.66 M CNY
The Harbin Pharmaceutical Group Co Operating Cash Flow history
YEAROperating Cash FlowYoY
439.66 MCNY-44.52%
792.50 MCNY-16.55%
949.67 MCNY+52.66%
622.09 MCNY-482.97%
-162.44 MCNY-77.69%
-728.15 MCNY+155.55%
-284.94 MCNY-141.13%
692.72 MCNY+364.23%
149.22 MCNY-94.63%
2.78 BCNY+67.35%
1.66 BCNY+46.12%
1.14 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

Operating Cash Flow of Harbin Pharmaceutical Group Co is 439.66 M CNY in 2025.

Operating Cash Flow of Harbin Pharmaceutical Group Co changed from 792.50 M CNY to 439.66 M CNY, representing a -44.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Harbin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Harbin Pharmaceutical Group Co

All Key Metrics — Harbin Pharmaceutical Group Co